Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00659360 · FLOW

Participant flow

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma · Source last updated 2018-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity. saracatinib: Given orally
    id
    FG000
    title
    Arm I AZD0530
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        17
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        17
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity. saracatinib: Given orally
    id
    FG000
    title
    Arm I AZD0530
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        17
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        17
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice